Short Communication · Volume 54, Issue 1, 19 December 2021 · Open Access
Molecular heterogeniety of β-Thalassemia in Karak District, Khyber Pakhtunkhwa, Pakistan
· · · ·
Affiliations & Notes ⌄
- 1Department of Biotechnology, University of Science and Technology, Bannu, Pakistan. 2Gomal University, Dera Ismail Khan, Pakistan. 3Mayo Hospital Lahore, Punjab, Pakistan. 4Women and Children Hospital, Bannu, KP, Pakistan. 5Institute of Biochemistry and Biotechnology, University of the Punjab, Lahore, Pakistan , * Corresponding author: sjabbarkhan@yahoo.com
Article Info ⌄
- Journal:
- Pakistan Journal of Zoology
- Published:
- 19 December 2021

From the article
- DNA from 200 individuals was screened for the presence of six β-thal mutations reported in Pakistani population.
- Only four point mutations; FSC 8/9 (HBB: c.27_28insG), IVS-1-5 (G>C) (HBB: c.92+5G>C), FSC 5 (-CT) (HBB: c.17_18delCT) and codon 15 (G>A) (HBB: c.47G>A) were found to be the most common in 181 patients (Table II).
- IVS, Intervening sequence; FSC, frameshift codon; Mt, mutant; N, normal.
- Consanguinity and lack of awareness and non-availability of health facilities have contributed to the high occurrence of β-thal and miserable life of the patients.
Selected from the article's own text.
Abstract
Materials and methods
The current study was undertaken in the Molecular Laboratory of the Department of Biotechnology, University of Science and Technology Bannu, KP, Pakistan. Different demographic parameters including sex, age, clinical symptoms and family history of β-thal with important pathological parameters were collected on a study-designed proforma . A written consent was obtained from patients and their parents. In total, 200 blood samples were collected from 110 unrelated families having at least one affected blood transfusion-dependent β-thal [Cooley’s anemia or β-thal major (β-TM)] child . The study was permitted by the Ethnic Board of the Thalassemia Center and Bannu University review board. The participating patients in the study were blood transfusion-dependent and diagnosed as β-TM patients through peripheral blood morphology and Hb electrophoresis Laboratory tests ; . Most of the families were inbred and patients were born due to consanguineous marriages. Socioeconomic status of the non-consanguineous families was more satisfactory than consanguineous . The genomic DNA from the collected blood samples was isolated using standard protocol . Screening the samples was done using tetra primer based allele specific PCR . Two PCR reactions were done either with allele specific primer or control primers (Table I). To perform PCR reaction, 100 ng genomic DNA, 200 µM of each dNTP, 1 unit of Taq polymerase, 10 pmol of each primer i.e. two primers for control fragment and two primers for each of the mutant or control allele and 1x Taq reaction buffer were used in 20 µ reaction volume. The reaction was done through 27 cycles, consisting of denaturation at 94°C for one minute, annealing at 65°C for one minutes and extension at 72°C for 1 minute and 30 seconds. Denaturation during the first cycle was done at 95°C for 6 minutes while the final extension was done at 72°C for 10 minutes. Gel electrophoresis of PCR product was done on 3% agarose gel, containing ethidium bromide for visualization. Hind III digest was used as a marker. β-globin genotypes were assigned on the basis of presence or absence of allele specific bands. The previously characterized samples and dH2O were used as positive and negative controls respectively.
Results
DNA from 200 individuals was screened for the presence of six β-thal mutations reported in Pakistani population. Only four point mutations; FSC 8/9 (HBB: c.27_28insG), IVS-1-5 (G>C) (HBB: c.92+5G>C), FSC 5 (-CT) (HBB: c.17_18delCT) and codon 15 (G>A) (HBB: c.47G>A) were found to be the most common in 181 patients (Table II). Nineteen patients remained uncharacterized for
Table I. The amplification refractory mutation system-polymerase chain reaction allele specific primers used in this study.
| Primers | Sequences (5'>3') | Product size (bp) |
| Control A | CAA TGT ATC ATG CCT CTT TGC ACC | 861 |
| Control B | GAC TCA AGG CTG AGA GAT GCA GGA | 861 |
| Common C | TCA CTT AGA CCT CAC CCT GTG GAG CCA C | - |
| Codons 41/42 (Mt) | GAG TGG ACA GAT CCC CAA AGG CCT TGT TAG | 439 |
| Codons 41/42 (N) | GAG TGG ACA GAT CCC CAA AGG ACT CAA AGA | - |
| IVS-1-5 (Mt) | CTC CTT AAA CCT GTC TTG TAA CCT TGT TAG | 285 |
| IVS-1-5 (N) | CTC CTT AAA CCT GTC TTG TAA CCT GAT ACG AAA | - |
| IVS-1-1 (Mt) | TTA AAC CTG TCT TGT AAC CTT GAT ACG AAA | 280 |
| IVS-1-1 (N) | GAT GAA GTT GGT GAC GCC CRG GGT AGG | - |
| FSC 8/9 (Mt) | CCT TGC CCC ACA GGG CAG TAA CGG CAC ACC | 215 |
| FSC 8/9 (N) | CCT TGC CCC ACA GGG CAG TAA CGG CAC ACT | - |
| Codon 15 (Mt) | CAC CAA CTT CAT CCA CG5 TCA CCT TGG CCT | 500 |
| Codon 15 (N) | CAC CAA CTT CAT CCA CGT TCA CCT TGG CCC | - |
| FSC (Mt) | ACA GGG CAG TAA CGG CAG ACT TCT ACT CG | 170 |
| FSC (N) | ACA GGG CAG TAA CGG CAG ACT TCT CAT CAG | - |
IVS, Intervening sequence; FSC, frameshift codon; Mt, mutant; N, normal.
Table II. The frequency of mutant alleles in the studied individuals.
| Serial number | HbVar nomenclature | Mutations | Homozygous | heterozygous | Total no. of mutant alleles (n) | Frequency (%) |
| 1 | HBB: c.27_28insG | FSC 8/9 (+G) | 34 | 57 | 125 | 49 |
| 2 | HBB: c.92+5G>C | IVS-I-5(G>C) | 21 | 32 | 74 | 29 |
| 3 | HBB: c.17_18delCT | FSC 5 (–CT) | 13 | 11 | 37 | 14.5 |
| 4 | HBB: c.47G>A | Codon 15 (G>A) | 06 | 07 | 19 | 7.5 |
| Total no (%) | 74 | 107 | 255 | 100.00% |
known 22 mutations reported so far in Pakistani community (Table II). Of the 181 characterized samples, 74 (40.88%) were found to be homozygous for four mutations and 107 (59.12%) were heterozygous for the same mutations. The frame-shift mutation at codon 8/9 (+G) was found to as the most prevalent mutation (49%), followed by IVS-I-5(G>C) (29%), codon 5 (-CT) (14.5%) and codon 15 ((G>A) (7.5%) (Table II). A total of 255 mutant alleles observed for the above mentioned four mutations. Of the 74 homozygous patients 34 (45.9%) had codon 8/9 (+G) mutation, 21(28.3%) possessed IVS-I-5(G>C), and 13 (17.6%) and 6 (8.1%) were homozygous for FSC 5 (–CT) and codon 15 (G>A) respectively (Table II). Similarly, maximum number of patients (57=53.3%) were found with codon 8/9 (+G) mutation out of 107 compound heterozygous thalassemia patients, followed by IVS-I-5(G>C) (29.9%), codon 5 (–CT) (9.4%), and only 6.5% patients with Codon 15 (G>A) mutation.
Moreover, out of 200 patients, 40 (20.0%) were reported to be over 15 years old, 110 (55.0%) patients demonstrated early onset of disease, i.e. <5 years old, and 50 (25.0%) patients were >10 years old. Furthermore, the study also showed 109 (54.5%) patients with poor socioeconomic status, having a monthly income of <20,000 PKR. The parents of 89 (44.5%) patients were first cousins, 84 (42.0%) were related but not first cousins, and 27 (13.5%) were not related. The above mentioned data suggests consanguinity as the main driving force behind the inheritance of β-thalassemia in KP province.
Discussion
Approximately 270 million carriers of hemoglobinopathies including 80 million β-thal have been estimated worldwide. Reviewing the previous reports, it can be concluded that 300,000–400,000 children with abnormal HbS including 23,000 β-thal are born every year . In Pakistan, β-thal is very common with an estimated inheritance rate of 5.0–7.0%, and over 9000 homozygous β-thal cases are born every year ; . About 35 β-thal mutations have been reported in the country . In every population or ethnic group, usually four to seven mutations are reported to be common, comprising nearly 90.0% of all β-thal cases . The frequency of homozygosity in Pakistan relates to certain aspects, the notable of which are frequent first-cousin marriages, increase in annual birth rates, contact with mutagens and migration of highly conserved and consanguineous Afghani population to Pakistan , 2019). Moreover, the increase in annual birth rate in Pakistan accelerates the number of homozygous thalassemic patients. From the Indian subcontinent, nearly 40 β-thal mutations have been identified, of which five, i.e. FSC 8/9 (+G), IVS-I-5 (G>C), codons 41/42 (-TCTT), IVS-I-1 (G>T) and FSC 5 (-CT), are predominant ; . It has been reported that the existing treatment strategies (i.e. chelation therapy, bone marrow transplantation, blood transfusion) may not eliminate the disease due to its high treatment cost and required conditions ; . The reasons for the numerous birth rate of β-thal patients and carriers in developing countries include lack of public awareness and lack of facilities in the form of thalassemia centers, molecular diagnosis, premarital screening and prenatal screening ; . This study reports four common mutations in the local population, which are in agreement with previous findings ; , 2019). Most Pashtuns prefer inter-family marriages. Interestingly, IVS-I-5(G>C) was reported as the second most common mutation in the region, which is contrary with the what has previously been reported , 2019). The above contradiction can be correlated to regional distribution of the Pathan tribes containing a large number of small tribal groups, unequal sample size and sample sites. The other reason for contradiction could be that the area is comparatively closer to the Afghan border and a large population has migrated here during the Russian invasion of Afghanistan.
Conclusion
Consanguinity and lack of awareness and non-availability of health facilities have contributed to the high occurrence of β-thal and miserable life of the patients. All the patients must be molecularly characterized before first transfusion.
Statement of conflict of interest
The authors have declared no conflict of interest.
References
- Ahmed, M.M., 2016. Ann. Punjab Med. Coll., 10: 11-19. https://doi.org/10.24312/paradigms100211[CrossRef]
- Ahmed, S., Saleem, M., Sultana, N., Raashid, Y., Waqar, A., Anwar, M., Modell, B., Karamat, K.A. and Petrou, M., 2000. Prenat. Diagn., 20: 378-383. https://doi.org/10.1002/(SICI)1097-0223(200005)20:5<378::AID-PD815>3.0.CO;2-7[CrossRef]
- Ansari, S.H., Shamsi, T.S., Ashraf, M., Bohray, M., Farzana, T., Tahir, M., Parveen , K., Erum , S., Ansari , I., Nadeem , M., Ahmed , M. and Raza , F., 2011. Intl. J. mol. Epidemiol. Genet., 2: 403.
- Arif, F., Fayyaz, J., and Hamid, A., 2008. J. Pak. med. Assoc., 58: 621-624.
- Chan, O.T., Westover, K.D., Dietz, I., Zehnder, J.I. and Schrijver, I., 2010. Am. J. clin. Pathol., 133: 700-707. https://doi.org/10.1309/AJCP7HQ2KWGHECIO[CrossRef]
- Hussain, A., Ahmed, S., Ali, N., Malik, S.H., Anees, M., Chuahdry, A.H., Ahmed, P., 2017. Hemoglobin, 41: 100-103. https://doi.org/10.1080/03630269.2017.1339612[CrossRef]
- Jalilian, M., Azizi, J.F., Ahmadi, F., Amini, R., Esfehani, H., Sosanian, M., Rabbani, B., Maleki, M., Mahdieh, N., 2017. Hemoglobin. 41: 61-64. https://doi.org/10.1080/03630269.2017.1302468[CrossRef]
- Khan, J., Ahmad, N., Siraj, S., and Hoti, N., 2015. Hemoglobin, 39: 95-101. https://doi.org/10.3109/03630269.2014.1002136[CrossRef]
- Khan, J., Dost, M., Ismail, M., Khan, I., Zia, R., Nias, S., 2019. J. Pak. med. Assoc., (ahead of print).
- Khan, N.M., Rehman, S.U., Shakeel, M., Khan, S., Ahmed, U., Rehman, H., Yaseen, T., Javed, A., 2018. Hemoglobin, 42: 91-95. https://doi.org/10.1080/03630269.2018.1487308[CrossRef]
- Kountouris, P., Lederer, C.W., Fanis, P., Feliki, X., Old, J., Kleanthous, M., 2014. PLoS One, 9: e103020. https://doi.org/10.1371/journal.pone.0103020[CrossRef]
- Liaska, A., Petrou, P., Georqakopolous, C.D., Diamanti, R., Papaconstantinou, D., Kanakis, M.G., Georgalas, I., 2016. BMC Ophthalmol., 16: 102. https://doi.org/10.1186/s12886-016-0285-2[CrossRef]
- Newton, C.R., Graham, A., Heptinstall, L.E., Powell, S.J., Summers, C., Kalsheker, N., Smith, J.S. and Markham, A.F., 1989. Nucl. Acid Res., 17: 2503-2516. https://doi.org/10.1093/nar/17.7.2503[CrossRef]
- Sambrook, J., 1987. Mol. Cloning, 3: E1-E39.
- Shakeel, M., Arif, M., Rehman, S.U. and Yaseen, T., 2016. Pak. J. med. Sci., 32: 491.
- Woods, C.G., Cox, J., Springell, K., Hampshire, D.J., Mohamed, M.D., McKibbin, M., Stern, R., Raymond, F.L., Sandford, R., Sharif, M.S., Karbani, G., Ahmed, M., Bond, J., Clayton, D. and Inglehearn, C.F., 2006. Am. J. Hum. Genet., 78: 889-896. https://doi.org/10.1086/503875[CrossRef]
Services
Article usage statistics
Loading…
